NYSE · CIK 0001837607
AEON AEON Biopharma, Inc.
Insider trading from SEC Form 4. Last filing Aug 21, 2026. Close $0.28 on Oct 9, 2026, +44% from the 52-week low and -80% from the high.
AEON Biopharma, Inc. (AEON) has 23 SEC Form 4 filings on file from 11 insiders, the latest filed on Aug 21, 2026. In the last 90 days insiders made 1 open-market buy worth $243k and 0 open-market sells worth $0, net +$243k.
3 open-market trades have been scored at AEON. The newest: Timothy P Lynch (10% owner) bought $243k of stock on Aug 19, 2026, filed Aug 21, 2026, scored 44 (moderate).
AEON closed at $0.28 on Oct 9, 2026, 44% above its 52-week low and 80% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at AEON Biopharma, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 44Moderate | Timothy P Lynch owner buy | $243k 1,150,000 shares | +21% | 0% from low-86% from high | |
| 31Weak | Jost Fischer director buy | $29k 60,000 shares | +29% | - | |
| 32Weak | Jost Fischer director buy | $55k 110,000 shares | +114% | - |
Transactions
Every row filed, 27 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | Timothy P Lynch owner | POpen-market purchase Class A Common Stock | +1,150,000 | $0.21 | $243k | 6,500,000 | Aug 21, 2026 |
| Jun 17, 2026 | Eric G Carter director | AGrant or award Class A Common Stock | +222,684 | $0.00 | $0 | 258,705 | Jun 22, 2026 |
| Jun 17, 2026 | Jost Fischer director | AGrant or award Class A Common Stock | +222,684 | $0.00 | $0 | 489,469 | Jun 22, 2026 |
| Jun 17, 2026 | Marc Forth director | AGrant or award Class A Common Stock | +222,684 | $0.00 | $0 | 973,231 | Jun 22, 2026 |
| Jun 17, 2026 | Robert J Palmisano director | AGrant or award Class A Common Stock | +222,684 | $0.00 | $0 | 258,705 | Jun 22, 2026 |
| Jun 17, 2026 | Shelley B Thunen director | AGrant or award Class A Common Stock | +222,684 | $0.00 | $0 | 258,705 | Jun 22, 2026 |
| Apr 2, 2026 | John Bencich CHIEF FINANCIAL OFFICER | AGrant or award Class A Common Stock | +754,717 | $0.00 | $0 | 754,717 | Apr 3, 2026 |
| Feb 17, 2026 | Chad Oh CHIEF MEDICAL OFFICER | AGrant or award Class A Common Stock | +862,500 | $0.00 | $0 | 866,564 | Mar 11, 2026 |
| Mar 4, 2026 | Chad Oh CHIEF MEDICAL OFFICER | AGrant or award Class A Common Stock | +1,316,872 | $0.00 | $0 | 2,183,436 | Mar 11, 2026 |
| Feb 17, 2026 | Jennifer Sy PRINCIPAL ACCOUNTING OFFICER | AGrant or award Class A Common Stock | +575,000 | $0.00 | $0 | 575,251 | Mar 5, 2026 |
| Feb 17, 2026 | Alexander Blair Wilson CLO, CSO, and Corp Secretary | AGrant or award Class A Common Stock | +862,500 | $0.00 | $0 | 866,133 | Mar 5, 2026 |
| Mar 4, 2026 | Jennifer Sy PRINCIPAL ACCOUNTING OFFICER | AGrant or award Class A Common Stock | +925,925 | $0.00 | $0 | 1,501,176 | Mar 5, 2026 |
| Mar 4, 2026 | Alexander Blair Wilson CLO, CSO, and Corp Secretary | AGrant or award Class A Common Stock | +1,316,872 | $0.00 | $0 | 2,183,005 | Mar 5, 2026 |
| Feb 17, 2026 | Robert E. Bancroft PRESIDENT & CEO | AGrant or award Class A Common Stock | +3,000,000 | $0.00 | $0 | 3,177,103 | Feb 19, 2026 |
| May 21, 2025 | Robert J Palmisano director | AGrant or award Restricted Stock Unitsderivative | +308,641 | $0.00 | $0 | 308,641 | May 23, 2025 |
| May 21, 2025 | Shelley B Thunen director | AGrant or award Restricted Stock Unitsderivative | +308,641 | $0.00 | $0 | 308,641 | May 23, 2025 |
| May 21, 2025 | Alexander Blair Wilson Exec VP, CLO & Corp Secretary | AGrant or award Restricted Stock Unitsderivative | +1,316,872 | $0.00 | $0 | 1,316,872 | May 23, 2025 |
| May 21, 2025 | Chad Oh Chief Medical Officer | AGrant or award Restricted Stock Unitsderivative | +1,316,872 | $0.00 | $0 | 1,316,872 | May 23, 2025 |
| May 21, 2025 | Jennifer Sy Chief Accounting Officer | AGrant or award Restricted Stock Unitsderivative | +925,925 | $0.00 | $0 | 925,925 | May 23, 2025 |
| May 21, 2025 | Marc Forth director | AGrant or award Restricted Stock Unitsderivative | +370,370 | $0.00 | $0 | 370,370 | May 23, 2025 |
| May 21, 2025 | Eric G Carter director | AGrant or award Restricted Stock Unitsderivative | +308,641 | $0.00 | $0 | 308,641 | May 23, 2025 |
| May 21, 2025 | Jost Fischer director | AGrant or award Restricted Stock Unitsderivative | +308,641 | $0.00 | $0 | 308,641 | May 23, 2025 |
| May 21, 2025 | Jost Fischer director | POpen-market purchase Class A Common Stock | +60,000 | $0.49 | $29k | 266,785 | May 23, 2025 |
| May 19, 2025 | Jost Fischer director | POpen-market purchase Class A Common Stock | +50,000 | $0.50 | $25k | 146,785 | May 21, 2025 |
| May 20, 2025 | Jost Fischer director | POpen-market purchase Class A Common Stock | +60,000 | $0.51 | $30k | 206,785 | May 21, 2025 |
| May 14, 2025 | Robert E. Bancroft President & CEO | AGrant or award Class A Common Stock | +177,103 | $0.00 | $0 | 177,103 | May 16, 2025 |
| Apr 29, 2025 | Robert E. Bancroft President & CEO | AGrant or award Stock Optionderivative | +59,034 | $0.00 | $0 | 59,034 | May 1, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Robert E. BancroftPRESIDENT & CEO
- John BencichCHIEF FINANCIAL OFFICER
- Eric G Carterdirector
- Jost Fischerdirector
- Marc Forthdirector
- Timothy P Lynchowner
- Chad OhCHIEF MEDICAL OFFICER
- Robert J Palmisanodirector
- Jennifer SyPRINCIPAL ACCOUNTING OFFICER
- Shelley B Thunendirector, officer
- Alexander Blair WilsonCLO, CSO, and Corp Secretary
Questions about AEON
Answered from the filings on this page, as of the latest one.
Are insiders buying AEON?
As of Aug 21, 2026, SEC Form 4 filings show 1 open-market buy worth $243k by 1 insider and 0 open-market sells worth $0 by 0 insiders at AEON Biopharma, Inc. in the last 90 days, net +$243k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade AEON on the open market?
Timothy P Lynch (10% owner) bought $243k of AEON on Aug 19, 2026 and filed the Form 4 on Aug 21, 2026. InsiderTell scored 44 (moderate).
How many insiders file Form 4 at AEON Biopharma, Inc.?
11 people have filed a Form 4 at AEON Biopharma, Inc., among them Robert E. Bancroft (PRESIDENT & CEO), John Bencich (CHIEF FINANCIAL OFFICER), Eric G Carter (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.